ArticleNature biotechnology2026
Sequence Display enables large-scale sequence-activity datasets for rapid protein evolution.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sequencing peptides by reversing translation.Nature biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Engineering proteins with desired functions remains challenging and usually requires multiple rounds of screening and selection. Here, we present Sequence Display, a platform that generates large-scale protein sequence-activity datasets in a single round. Sequence Display enables multiplexed assessment of individual variant activity within a single experiment, offering a robust approach to mapping detailed sequence-function relationships. We demonstrate the platform's broad applicability by generating datasets for cytosine deaminase, uracil glycosylase inhibitor, aminoacyl-tRNA synthetase and a compact Cas9 nuclease. Integrating these datasets obtained from Sequence Display with pretrained protein language models, fine-grained, variant-specific activity landscapes can be constructed. We discovered several Cas9 variants with expanded protospacer-adjacent motif recognition and evolved aminoacyl-tRNA synthetase variants capable of recognizing different noncanonical amino acids. Together, this study establishes Sequence Display as a powerful tool for mapping protein activity landscapes and accelerating the discovery of optimized proteins for biological and medical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.